CAR T cell therapy has emerged as one of the most promising immunotherapies for blood cancers like leukemia, offering patients a tailored assault on malignant cells by reprogramming their own immune systems. Despite impressive clinical successes, a significant fraction of patients relapse, and many suffer serious adverse effects. Scientists have long grappled with the difficulty of accurately predicting patient responses or refining these therapies due to the limitations of current preclinical testing models. Conventional two-dimensional cell cultures often fail to replicate the intricate biological environments where cancer and immune cells interact, while animal models are labor-intensive, costly, and sometimes poorly predictive of human outcomes.

This innovative device, the size of a standard microscope slide, takes a giant leap forward by replicating the three-dimensional architecture and immunological complexity of the human bone marrow — the primary niche where leukemia cells thrive. Crucially, it incorporates not just the physical structure but also a functioning human immune system, enabling real-time observations of CAR T cell dynamics in an authentic microenvironment. The chip’s design includes three distinct bone marrow regions: blood vessels, the surrounding marrow cavity, and the outer bone lining, all populated with patient-derived bone marrow cells that self-organize and secrete key extracellular matrix components such as collagen, fibronectin, and laminin. This self-assembly recreates the native tissue architecture and its multifaceted immune ecosystem.

The technical sophistication of this “bone marrow on a chip” permits the formation of vascularized niches that maintain realistic immune cell trafficking and interactions. This is a notable departure from traditional models that lack vascular complexity, often resulting in oversimplified or inaccurate assessments of therapeutic action. Using high-resolution imaging and advanced microscopy, the research team tracked individual CAR T cells as they navigated the microvascular networks, detected leukemia targets, and executed cytotoxic attacks. They observed with unprecedented clarity how CAR T cells slow their motility upon encountering malignant cells, facilitating direct engagement and destruction — a dynamic process previously difficult to capture in vitro or in animal models.

Beyond direct antitumor activity, the study revealed a fascinating “bystander effect,” where engineered CAR T cells stimulate non-targeted endogenous immune cells within the device. This interplay may shed light on both the therapeutic potentiation and adverse inflammatory side effects observed in patients, pointing to new avenues for modulating immune responses to maximize efficacy while minimizing toxicity. The chip also proved capable of modeling clinical scenarios including complete remission, resistance to therapy, and relapse, offering a powerful platform to study mechanisms underlying these varied outcomes.

A remarkable advantage of this platform is its scalability and time efficiency. While traditional animal models can take months to establish and require complex protocols, the leukemia-on-a-chip system can be assembled within half a day and supports experimental assays extending up to two weeks. This rapid turnaround opens the door for personalized medicine applications, where patient-specific bone marrow samples can be cultured and tested against multiple CAR T cell designs before selecting the optimal therapeutic approach.

The research team demonstrated that next-generation “fourth generation” CAR T cells, which incorporate enhanced engineering features for improved persistence and potency, outperformed earlier versions at lower dosages within the chip environment. This suggests the device’s utility in optimizing dose regimens and therapy formulations, potentially reducing toxic side effects while maintaining efficacy. Overall, this bioengineered platform represents an integrated, immunocompetent preclinical trial tool that bridges an important gap between bench research and patient care.

As regulatory agencies such as the FDA announce plans to phase out animal testing for drug safety evaluation, the timing of this breakthrough could not be more significant. By providing a physiologically relevant, animal-free model for immunotherapy testing, the leukemia-on-a-chip aligns with the drive toward humane, cost-effective, and predictive research alternatives. The device’s capacity to model dynamic, systemic immune responses within a controlled setting enables extensive mechanistic studies that can guide rational design of novel immunotherapies for leukemia and potentially other cancers.

This multidisciplinary collaboration underscores the power of combining mechanical engineering, microfluidics, cellular biology, and immunology to tackle complex challenges in cancer research. By harnessing patient-derived cells and reproducing the intricacies of the leukemia niche, researchers now have a cutting-edge tool to dissect immunotherapy resistance, identify biomarkers of response, and fine-tune treatments prior to clinical trials. The prospect that clinicians might one day leverage this technology to personalize therapy selection, improving outcomes and reducing side effects, heralds a new era in precision oncology.

The implications extend beyond leukemia alone. This platform’s modular design and ability to mimic tumor-immune interactions pave the way for similar “organ-on-a-chip” models targeting solid tumors and other hematologic malignancies. The convergence of bioengineering and immunotherapy now promises to accelerate the translation of laboratory insights into real-world cures in a timeframe and cost structure previously unimaginable.

In sum, the bioengineered leukemia-on-a-chip stands as a testament to innovation at the interface of engineering and medicine. It is poised to become a pivotal asset in the battle against cancer, not only enhancing our understanding of CAR T cell behavior in physiologically relevant contexts but also empowering clinicians and scientists to forge truly personalized treatment regimens. As this technology matures, it offers hope that the next wave of immunotherapies will be smarter, safer, and more effective, transforming lives for patients facing leukemia across the globe.

Subject of Research: Cells

Article Title: Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia

News Publication Date: 1-Jul-2025

Web References:

• Original article DOI: 10.1038/s41551-025-01428-2
• University of Pennsylvania Perelman School of Medicine: https://www.med.upenn.edu/
• FDA announcement on animal testing phase-out: https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs

Image Credits: NYU Tandon Applied Micro-Bioengineering Laboratory/Courtesy of Weiqiang Chen

Keywords: Chimeric antigen receptor therapy, Blood cancer, Leukemia, Cancer treatments, Cancer immunotherapy, Biomedical engineering

Traditional methods for testing cancer therapies, especially CAR T-cell treatments, have long relied on animal models or standard in vitro assays, both of which suffer from significant limitations. Animal models, while valuable, fail to mirror the intricacy of human immune responses adequately and require months of preparation and observation. Conversely, conventional lab tests do not replicate the dynamic interactions between cancer cells and immune effectors in their native microenvironment. The new bioengineered leukemia chip addresses these challenges head-on by authentically reconstituting the three critical bone marrow regions: blood vessels, the marrow cavity, and the outer bone lining. This structural fidelity is complemented by the system’s ability to self-organize and generate extracellular matrix proteins such as collagen, fibronectin, and laminin, thereby preserving the native immune milieu crucial for accurate functional analysis.

What sets this leukemia-on-a-chip apart is its integration of patient-derived bone marrow cells, offering a personalized and immunocompetent platform for real-time visualization and functional interrogation. Using cutting-edge imaging technologies, researchers captured the behavior of CAR T-cells as they navigated the vascular spaces, identified leukemic cells, and executed targeted cytotoxic actions. Such dynamic observation revealed that engineered immune cells exhibit purposeful motility: they actively patrol their environment, decelerate upon encountering malignant cells, and engage in sequential killing—a process that was previously inscrutable in living human tissues.

Importantly, the team identified a “bystander effect” phenomenon, wherein the activated CAR T-cells stimulate ancillary immune cells not directly engineered for targeting leukemia. This finding provides critical insight into the therapy’s wider immunological impact and may underpin both its therapeutic efficacy and adverse side effects, including cytokine release syndrome. Such a discovery underscores the nuanced interplay between engineered and natural immune components, advancing our understanding of patient response variability and toxicity profiles.

The leukemia chip further enabled simulation of diverse clinical scenarios frequently observed in patients undergoing CAR T-cell therapy. By manipulating the system parameters, the researchers recreated states such as complete remission, therapeutic resistance, and transient response followed by relapse. These models allowed comparative evaluation of next-generation “fourth-generation” CAR T-cells, which possess enhanced design attributes aimed at improving performance. The study demonstrated that these advanced CAR T-cells achieved superior leukemia clearance, particularly at reduced doses, highlighting their potential to increase treatment efficacy while minimizing side effects.

One of the most remarkable advantages of this technology is its rapid assembly and operational capacity, which sharply contrasts with the protracted timelines required for animal studies. The leukemia-on-a-chip can be fabricated in approximately half a day and sustain experiments lasting up to two weeks. This expedited workflow not only accelerates therapeutic screening but also aligns with regulatory trends, such as the recent FDA initiative to phase out mandatory animal testing for drug development, thereby addressing ethical considerations and reducing costs.

The system’s utility extends beyond visualization, incorporating a computational “matrix-based analytical and integrative index” that quantitatively assesses multiple facets of immune response within the tested environment. This multidimensional metric enhances the predictive power of preclinical models, offering clinicians a robust tool to forecast the success of specific CAR T-cell therapies for individual patients. By delivering granular data on cellular dynamics and therapy outcomes, the chip paves the way for truly personalized immunotherapy regimens.

The implications of this innovation are transformative. As Professor Chen articulates, the technology holds promise to shift cancer treatment paradigms from a one-size-fits-all methodology to bespoke therapeutic strategies based on comprehensive pre-treatment testing. Such precision medicine approaches have the potential to optimize patient outcomes, reduce adverse reactions, and streamline clinical decision-making in hematological oncology.

Collaboration was integral to this project, drawing expertise from multidisciplinary teams across NYU Tandon, the University of Colorado Anschutz Medical Campus, NYU Grossman School of Medicine, and the University of Pennsylvania. The research was supported by notable institutions including the National Science Foundation, National Institutes of Health, and several cancer research foundations dedicated to advancing immunotherapy development.

This leukemia-on-a-chip not only marks a technological milestone but also represents a powerful example of how engineering innovations can intersect with biomedical science to accelerate translational medicine. Its capacity to emulate a complex human tissue niche within a manageable and observable model holds promises for expanding beyond leukemia to other cancers and immune-related diseases.

With the convergence of advanced bioengineering, immunology, and computational analytics, this device could usher in a new era of preclinical testing platforms. Such platforms may ultimately reduce reliance on animal models, hasten experimental throughput, refine therapeutic design, and most importantly, enhance the clinical management of patients afflicted by hematological malignancies globally.

In sum, this cutting-edge preclinical tool embodies the future of immunotherapy development by bridging the gap between laboratory research and patient-specific treatment optimization. By providing unprecedented clarity into immune-cancer cell interactions and enabling rapid, comprehensive therapy evaluation, it stands as a beacon for personalized medicine in the fight against leukemia, inspiring hope for improved outcomes and innovative cancer care solutions.

Subject of Research: Not applicable
Article Title: Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia
News Publication Date: 1-Jul-2025
Web References:

• https://engineering.nyu.edu/faculty/weiqiang-chen
• https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs
• https://www.fda.gov/media/186092/download?attachment
• https://www.nature.com/articles/s41551-025-01428-2
• http://dx.doi.org/10.1038/s41551-025-01428-2
  References: Article published in Nature Biomedical Engineering
  Keywords: Bioengineering, CAR T-cell therapy, leukemia, immunotherapy, preclinical model, organ-on-a-chip, tumor microenvironment, bone marrow mimicry, personalized medicine, immunocompetent model, alternative to animal testing